The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 526.00
Bid: 526.00
Ask: 527.00
Change: -3.00 (-0.57%)
Spread: 1.00 (0.19%)
Open: 530.00
High: 530.00
Low: 524.00
Prev. Close: 529.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AuM Update

11 Jan 2024 07:00

RNS Number : 3134Z
Polar Capital Holdings PLC
11 January 2024
 

11 January 2024 Polar Capital Holdings plc

AuM Update

 

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM") and performance fees earned for the financial year to 31 March 2024.

 

Group AUM (unaudited)

 

Polar Capital reports that as at 31 December 2023, AuM were £19.6bn compared to £19.2bn at the end of March 2023, an increase of 2% over the period. During the nine-month period the £400m increase in AuM resulted from a £2.1bn increase relating to market movement and fund performance offset by net redemptions of £1.7bn.

 

AuM movement in nine months to 31 December 2023

Open ended

funds

Investment

Trusts

Segregated mandates

Total

AuM at 1 April 2023

£14,281m

£3,910m

£1,029m

£19,220m

Net flows

£(1,375)m

£(113)m

£(181)m

£(1,669)m

Fund closures1

£(7)m

-

£(43)m

£(50)m

Market movement

and performance

£1,336m

£705m

£18m

£2,059m

Total AuM at

31 December 2023

£14,235m

£4,502m

£823m

£19,560m

1 Return of funds to investors on closure of the Melchior European Absolute Return fund (Q1) and related segregated mandate (Q2).

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits (after the deduction of staff interests) earned in the first nine months of the Group's financial year.

 

Performance fee profit

net of staff allocations

Nine months to

31 Dec 22

Year to

31 Mar 23

(year-end)

Nine months to

31 Dec 23*

Net performance fee profit

£1.9m

£1.7m

£9.6m*

 

\* The figures to December 2023 are enhanced by what is expected to be approximately £0.6m of net deferment adjustments.

 

Gavin Rochussen, Chief Executive, commented:

 

"A strong rally in all major indices in the final calendar quarter of 2023, meant that our AuM at the end of the nine-month period were £19.6bn compared to £19.1bn at the end of the previous quarter and £19.2bn at the end of March 2023, despite net outflows over the period.

 

"In the quarter we benefited from continued net inflows of £45m into the Emerging Markets and Asian Stars funds and £28m into the Smart Energy Fund.

 

"Despite global equity markets rallying in the final quarter, the 'risk-off' stance by investors resulted in net outflows in the quarter of £1.1bn as clients reduced their weighting to active equities, taking profits in many cases following a strong period of performance. Net outflows for the nine months amounted to £1.7bn.

 

"In the quarter several clients continued to reduce their exposure to equities generally, directly impacting several Polar Capital funds including the Biotechnology Fund (£311m) and UK Value Fund (£238m) despite impressive absolute fund performance and strong performance relative to benchmark. Investors also continued to reduce weightings in our Technology funds and the European Opportunities Fund with net outflows of £136m and £230m in these strategies respectively. Overall, redemptions were concentrated in terms of number of clients, as opposed to representative of a wider trend.

 

"With peak interest rates in sight and declining inflation rates, investors will, we believe, begin to seek additional exposure to equities. We have a strong pipeline of client interest and have capacity to meet investor demand for our specialist active fund strategies. At the end of the quarter, we launched a Financial Credit Fund, managed by our Financials team, to further add to our offering.

 

"Performance fee profits, net of staff allocations, amounted to £9.6m compared to £1.7m in the prior year. While four funds earned a performance fee, most of the amount related to one fund.

 

"Long term performance remains strong with 81% of AuM outperforming respective benchmarks since inception.

 

"We remain confident that with our diverse range of differentiated, active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)

Samir Ayub (Finance Director)

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

Stephen Westgate

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

John Welch

Sam Milford

 

+44 (0)20 3597 8680

 

Camarco

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4995

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBMMPTMTJBBAI
Date   Source Headline
26th Apr 202410:33 amRNSForm 8.3 - RENALYTIX PLC
17th Apr 20243:55 pmRNSDirector/PDMR Shareholding
12th Apr 20245:43 pmRNSHolding(s) in Company
11th Apr 20247:00 amRNSAuM Update
9th Apr 20244:01 pmRNSChange of Company Secretary
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.